A new study funded by the NIMH suggests GLYX-13, a molecular cousin to ketamine, induces similar antidepressant results without the negative side effects of the well known street drug.
in a mouse model of Rett syndrome, researchers were able to reverse abnormalities in brain activity and improve neurological function by treating animals with an FDA-approved anesthesia drug, ketamine.
Scientists have discovered a biological marker that may help to identify which depressed patients will respond to an experimental, rapid-acting antidepressant like ketamine. The brain signal, detectable by noninvasive imaging, also holds clues to the agent's underlying mechanism, which are vital for drug development, say NIH researchers.
